Skip to main navigation

Top

Skip to main content

About Us

About Us
Genetically Defined Diseases

Genetically Defined Diseases
Pipeline

Pipeline
Patients & Partners

Patients & Partners
Investors

Investors
Inside Agios

Inside Agios

Press Releases

Investors Overview
News & Events
Stock Information
Corporate Governance
Financials
IR Resources

Year

Aug 11, 2022

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

Read More

PDF Version

Aug 08, 2022

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

Read More

PDF Version

Aug 04, 2022

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

Read More

PDF Version

Jul 14, 2022

Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022

Read More

PDF Version

Jul 12, 2022

Agios Appoints Brian Goff as Chief Executive Officer

Read More

PDF Version

Jun 10, 2022

Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

Read More

PDF Version

May 16, 2022

Agios Announces Evolution of Research Organization

Read More

PDF Version

May 12, 2022

Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

Read More

PDF Version

May 10, 2022

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

Read More

PDF Version

May 05, 2022

Agios Reports Business Highlights and First Quarter 2022 Financial Results

Read More

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Latest Earnings Call View Replay
Latest Form 10-K View PDF
Email Alerts Sign Up
Corporate Fact Sheet View PDF
Corporate Responsibility View PDF

Connect with us on LinkedIn or follow us on Twitter as we push forward into changing the landscape for people with genetically defined diseases.

Connect on LinkedIn

Follow us our Twitter

Contact
About Us
Patients & Partners
Careers

Agios Pharmaceuticals, Inc. © 2022

All right reserved.

Cookies Preferences
Copyright Info
Compliance
Sitemap
Privacy Notice
Terms of Use